September 14th 2024
Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared to chemoradiotherapy alone in patients with high-risk locally advanced cervical cancer.
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Tisotumab Vedotin Shows Potential in Cervical Cancer With Disease Progression
October 27th 2023In an interview with Targeted Oncology, Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.
Read More
Induction Chemotherapy Before Chemoradiation Betters Survival in Locally Advanced Cervical Cancer
October 23rd 2023Data presented at the 2023 ESMO Congress and showed that induction chemotherapy followed by chemoradiation reduced the risk of progression or death by 35% vs chemoradiation alone in patients with cervical cancer.
Read More
Pembrolizumab/Chemoradiotherapy Shows Clinically Meaningful PFS Improvement in Cervical Cancer
October 20th 2023Data from the KEYNOTE-A18 trial support the addition of pembrolizumab to chemoradiotherapy, which has been in place as standard of care for patients with newly diagnosed, previously untreated, high-risk locally advanced cervical breast cancer since 1999.
Read More
PDS0101 and CRT Displays Encouraging Early Data in Cervical Cancer
October 4th 2023Midway through the IMMUNOCERV trial, PDS0101 enhances the production of versatile CD8 killer T cells, leading to reduced tumor DNA and significant tumor shrinkage of over 60% in all patients with high-risk cervical cancer.
Read More
FDA Grants Priority Review to Pembrolizumab/Chemoradiotherapy in Cervical Cancer
September 20th 2023A supplemental biologics license application seeking the approval of pembrolizumab, external beam radiotherapy, and concurrent chemotherapy, followed by brachytherapy has been accepted for priority review by the FDA for advanced cervical cancer.
Read More
Considering Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer
July 28th 2023According to Bradley J. Monk, MD, FACS, FACOG, et al, multiple studies have shown the potential of tisotumab vedotin in patients with recurrent or metastatic cervical cancer. More evidence is needed before the oncology community can fully adopt its use.
Read More
Adding Pembrolizumab Extends OS and PFS in Key Subgroups in Recurrent, Metastatic Cervical Cancer
June 6th 2022Results from the KEYNOTE-826 trial showed that chemotherapy plus pembrolizumab with or without bevacizumab improved overall survival and progrssion-free survival in patients with metastatic cervical cancer based on subgroups including histology and prior treatment type.
Read More